Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Clinical trial NCT00063141 · COMPLETED
Trial details
- NCT number
- NCT00063141
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2003-04-01
- Primary completion
- 2006-06-01
- Enrollment
- 1302
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.